CN Patent

CN115737643A — 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素

Assigned to Aragon Pharmaceuticals Inc · Expires 2023-03-07 · 3y expired

What this patent protects

本文描述了用于治疗非转移性去势抵抗性前列腺癌的抗雄激素。

USPTO Abstract

本文描述了用于治疗非转移性去势抵抗性前列腺癌的抗雄激素。

Drugs covered by this patent

Patent Metadata

Patent number
CN115737643A
Jurisdiction
CN
Classification
—
Expires
2023-03-07
Drug substance claim
No
Drug product claim
No
Assignee
Aragon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.